|
|
Blood, 15 July 2004, Vol. 104, No. 2, pp. 543-549.
Prepublished online as a Blood First Edition Paper on March 25, 2004; DOI 10.1182/blood-2003-10-3545.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma
Chrystelle Guiter,
Isabelle Dusanter-Fourt,
Christiane Copie-Bergman,
Marie-Laure Boulland,
Sabine le Gouvello,
Philippe Gaulard,
Karen Leroy, and
Flavia Castellano
From the U617, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris XII/Département de Pathologie, Créteil, France; U581, INSERM, Laboratoire d'Immunologie Biologique, Hôpital Henri Mondor, Créteil, France; and Unité INSERM 567/CNRS UMR 8104, Département d'Hématologie, Hôpital Cochin, Paris, France.
Primary mediastinal large B-cell lymphoma (PMBL), currently recognized as a diffuse large B-cell lymphoma (DLBCL) subtype, shows increased expression of interleukin 4 (IL-4)/IL-13 signaling effectors and targets, suggesting constitutive activation of these pathways. We therefore investigated the functional state of the signal transducer and activator of transcription 6 (STAT6), mediating IL-4/IL-13 transcriptional effects. Constitutive STAT6 phosphorylation and DNA-binding activity were detected in PMBL cell lines but not DLBCL cell lines. Moreover, immunohistochemical analysis revealed nuclear phosphorylated STAT6 (P-STAT6) in 8 of 11 PMBL, compared with 1 of 10 DLBCL primary tumors (P = .01). IL-4 and IL-13 transcripts were absent in PMBL cell lines and expressed at low levels in tumors, indicating that, contrary to classical Hodgkin lymphoma (cHL), STAT6 activation is not due to an autocrine IL-4/IL-13 secretion. We demonstrated an amplification of the JAK2 gene in 2 of 6 PMBL cases, and showed higher JAK2 mRNA levels in PMBL compared with DLBCL (P = .005). The Janus kinase 2 (JAK2) was constitutively phosphorylated in the PMBL MedB1 cell line. MedB1 treatment with JAK2 inhibitor AG490 partially decreased STAT6 phosphorylation, suggesting that JAK2 is partially involved in STAT6 activation in these cells. Our findings highlight phosphorylated STAT6 as a characteristic distinguishing PMBL from DLBCL, but a common feature to PMBL and cHL, supporting the hypothesis of common pathogenic events in these 2 lymphomas. (Blood. 2004;104: 543-549)

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. H. Cho, S. Goenka, T. Henttinen, P. Gudapati, A. Reinikainen, C. M. Eischen, R. Lahesmaa, and M. Boothby
PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells
Blood,
March 12, 2009;
113(11):
2416 - 2425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. B. Ding, J. J. Yu, R. Y.-L. Yu, L. M. Mendez, R. Shaknovich, Y. Zhang, G. Cattoretti, and B. H. Ye
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
Blood,
February 1, 2008;
111(3):
1515 - 1523.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mottok, C. Renne, K. Willenbrock, M.-L. Hansmann, and A. Brauninger
Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6
Blood,
November 1, 2007;
110(9):
3387 - 3390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. W. Popov, G. Moldenhauer, B. Wotschke, S. Bruderlein, T. F. Barth, K. Dorsch, O. Ritz, P. Moller, and F. Leithauser
Target Sequence Accessibility Limits Activation-Induced Cytidine Deaminase Activity in Primary Mediastinal B-Cell Lymphoma
Cancer Res.,
July 15, 2007;
67(14):
6555 - 6564.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-L. Boulland, J. Marquet, V. Molinier-Frenkel, P. Moller, C. Guiter, F. Lasoudris, C. Copie-Bergman, M. Baia, P. Gaulard, K. Leroy, et al.
Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation
Blood,
July 1, 2007;
110(1):
220 - 227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Goenka, S. H. Cho, and M. Boothby
Collaborator of Stat6 (CoaSt6)-associated Poly(ADP-ribose) Polymerase Activity Modulates Stat6-dependent Gene Transcription
J. Biol. Chem.,
June 29, 2007;
282(26):
18732 - 18739.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Aoudjehane, P. Podevin, O. Scatton, P. Jaffray, I. Dusanter-Fourt, G. Feldmann, P.-P. Massault, L. Grira, A. Bringuier, B. Dousset, et al.
Interleukin-4 induces human hepatocyte apoptosis through a Fas-independent pathway
FASEB J,
May 1, 2007;
21(7):
1433 - 1444.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Rubenstein, J. Fridlyand, A. Shen, K. Aldape, D. Ginzinger, T. Batchelor, P. Treseler, M. Berger, M. McDermott, M. Prados, et al.
Gene expression and angiotropism in primary CNS lymphoma
Blood,
May 1, 2006;
107(9):
3716 - 3723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Savage, N. Al-Rajhi, N. Voss, C. Paltiel, R. Klasa, R. D. Gascoyne, and J. M. Connors
Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience
Ann. Onc.,
January 1, 2006;
17(1):
123 - 130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Levine, M. Loriaux, B. J. P. Huntly, M. L. Loh, M. Beran, E. Stoffregen, R. Berger, J. J. Clark, S. G. Willis, K. T. Nguyen, et al.
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
Blood,
November 15, 2005;
106(10):
3377 - 3379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. S. Lossos
Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6351 - 6357.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Campo
Holes in SOCS in primary mediastinal large B-cell lymphoma
Blood,
March 15, 2005;
105(6):
2244 - 2245.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Melzner, A. J. Bucur, S. Bruderlein, K. Dorsch, C. Hasel, T. F. E. Barth, F. Leithauser, and P. Moller
Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line
Blood,
March 15, 2005;
105(6):
2535 - 2542.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|